LncRNA ELF3-AS1 is a Prognostic Biomarker and Correlated with Immune Infiltrates in Hepatocellular Carcinoma

Table 4

Association of OS and clinical characteristics in TCGA HCC patients (Cox regression).

Characteristics	Total(N)	Univariate analysis		Multivariate analysis
		Hazard ratio (95% CI)	value	Hazard ratio (95% CI)	value
T stage (T3 & T4 & T2 vs. T1)	370	2.126 (1.481–3.052)	<0.001	1.261 (0.765–2.078)	0.363
Pathologic stage (Stage III & Stage IV vs. Stage I & Stage II)	349	2.504 (1.727–3.631)	<0.001	1.866 (1.142–3.047)	0.013
Tumor status (with tumor vs. tumor free)	354	2.317 (1.590–3.376)	<0.001	1.783 (1.193–2.666)	0.005
Gender (male vs. female)	373	0.793 (0.557–1.130)	0.200
Race (Asian and black or African American vs. white)	361	0.791 (0.551–1.135)	0.203
Age (>60 vs. ≤60)	373	1.205 (0.850–1.708)	0.295
Weight (>70 vs. ≤70)	345	0.941 (0.657–1.346)	0.738
Height (≥170 vs. <170)	340	1.232 (0.849–1.788)	0.272
BMI (>25 vs. ≤25)	336	0.798 (0.550–1.158)	0.235
Residual tumor (R1 & R2 vs. R0)	344	1.604 (0.812–3.169)	0.174
Histologic grade (G3 & G4 vs. G1 & G2)	368	1.091 (0.761–1.564)	0.636
Adjacent hepatic tissue inflammation (mild and severe vs. none)	236	1.194 (0.734–1.942)	0.475
AFP (ng/ml) (>400 vs. ≤400)	279	1.075 (0.658–1.759)	0.772
Albumin(g/dl) (≥3.5 vs. <3.5)	299	0.897 (0.549–1.464)	0.662
Prothrombin time (>4 vs. ≤4)	296	1.335 (0.881–2.023)	0.174
Child-Pugh grade (B & C vs. A)	240	1.643 (0.811–3.330)	0.168
Fibrosis Ishak score (1/2 & 3/4 & 5/6 vs. 0)	214	0.772 (0.465–1.281)	0.316
Vascular invasion (yes vs. no)	317	1.344 (0.887–2.035)	0.163
ELF3-AS1 (high vs. low)	373	1.841 (1.292–2.624)	<0.001	1.667 (1.127–2.468)	0.011